

**WEST**[Help](#)[Logout](#)[Interrupt](#)
[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#)
**Search Results -****Terms****Documents**

l9 and (obesity or leptin)

0

US Patents Full-Text Database  
 US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index

Case: IBM Technical Disclosure Bulletins

[Refine Search:](#)**BEST AVAILABLE COPY**[Clear](#)**Search History****Today's Date: 5/7/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	l9 and (obesity or leptin)	0	L10
USPT,PGPB,JPAB,EPAB,DWPI	prockop-d\$.in.	57	L9
USPT,PGPB,JPAB,EPAB,DWPI	17 and ((obesity adj1 protein) or leptin)	7	L8
USPT,PGPB,JPAB,EPAB,DWPI	l4 or l6	723	L7
USPT,PGPB,JPAB,EPAB,DWPI	marrow adj1 stroma\$1	561	L6
USPT,PGPB,JPAB,EPAB,DWPI	l4 near5 carrier\$1	11	L5
USPT,PGPB,JPAB,EPAB,DWPI	(mesenchymal adj1 stem adj1 cell\$1)	208	L4
USPT,PGPB,JPAB,EPAB,DWPI	l2 and (transfect\$ or transduc\$)	26	L3
USPT,PGPB,JPAB,EPAB,DWPI	l1 and gene	30	L2
USPT,PGPB,JPAB,EPAB,DWPI	human near5 (obesity adj1 protein)	38	L1

**WEST** **Generate Collection**

L16: Entry 4 of 6

File: USPT

Sep 5, 2000

DOCUMENT-IDENTIFIER: US 6114113 A

TITLE: High efficiency genetic modification method

## DEPR:

Erythropoietin (EPO) and leptin can also be expressed *in vivo* from genetically modified T cells according to the methods of the invention. For instance EPO is useful in gene therapy treatment of a variety of disorders including anemia (see International Publication No. WO 95/13376 entitled "Gene Therapy for Treatment of Anemia"). Sustained delivery of leptin by the methods of the invention is useful in treatment of obesity. See International Publication No. WO 96/05309 for a description of the leptin gene and the use thereof in the treatment of obesity.

## DEPR:

Pluripotent stem cells then differentiate into lymphoid stem cells, bone marrow stromal cells, T cell progenitors, B cell progenitors, thymocytes, T.sub.H Cells, T.sub.C cells, and B cells. This differentiation is modulated by growth factors such as IL-3, IL-4, IL-6, IL-7, GM-CSF, M-CSF, G-CSF, IL-2, and IL-5.

## CCXR:

435/440

## CCXR:

435/455

**WEST****Freeform Search****Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Term:****Display:**

10

Documents in Display Format:

CIT

Starting with Number

1

**Generate:**  Hit List  Hit Count  Image**Search History****Today's Date: 5/7/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	l15 and (obesity or leptin)	6	<u>L16</u>
USPT,PGPB,JPAB,EPAB,DWPI	l14 and l7	129	<u>L15</u>
USPT,PGPB,JPAB,EPAB,DWPI	l11 or l12 or l13	6816	<u>L14</u>
USPT,PGPB,JPAB,EPAB,DWPI	((424/93.21 )!.CCLS. )	398	<u>L13</u>
USPT,PGPB,JPAB,EPAB,DWPI	((536/23.5  536/24.1  536/24.2 )!.CCLS. )	5526	<u>L12</u>
USPT,PGPB,JPAB,EPAB,DWPI	((435/440  435/455  435/372  435/352 )!.CCLS. )	1374	<u>L11</u>
USPT,PGPB,JPAB,EPAB,DWPI	l9 and (obesity or leptin)	0	<u>L10</u>
USPT,PGPB,JPAB,EPAB,DWPI	prockop-d\$.in.	57	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI	l7 and ((obesity adj1 protein) or leptin)	7	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI	l4 or l6	723	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI	marrow adj1 stroma\$1	561	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI	l4 near5 carrier\$1	11	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI	(mesenchymal adj1 stem adj1 cell\$1)	208	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI	l2 and (transfect\$ or transduc\$)	26	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI	l1 and gene	30	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI	human near5 (obesity adj1 protein)	38	<u>L1</u>